Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Kaken Pharmaceutical
With
Dow Pharmaceutical Sciences
Age
18–64
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Has a clear diagnosis of AD meeting the Hanifin and Rajka criteria for AD that involves both the head/neck and the torso/limbs, and affects 5-30% of the subject's total BSA as determined using the rule of nines
Has a Baseline IGSS of 3(moderate) or 4(severe) in the selected treatment area on the torso/limbs, and a Baseline IGSS of 2(mild), 3(moderate) or 4(severe) in the selected treatment area on the head/neck.
Female of childbearing potential has a negative pregnancy test and will be using an effective method of contraception during the study.
You may not be if
Female who is pregnant, nursing an infant, or planning a pregnancy during the study period.
Has a Baseline oozing/crusting score of 3(moderate) or greater at the selected treatment area on the head/neck or torso/limbs.
Presence of a concurrent skin condition that could interfere with assessment of treatment.
Treatment with any investigational drug or device within 30 days or 5 half lives(whichever is longer) prior to the Baseline visit, or concurrent participation in another clinical trial with an investigational drug or device.
